Merck Stock Pulls Back After Meeting Expectations
Merck's stock price has pulled back from its all-time high of $154.49, reaching $149.54 as of August 27 at 3:59 PM EDT. This represents a -3.2% decline. The company's pipeline catalyst was the Phase 3 adjuvant melanoma data for its personalized mRNA cancer vaccine, intismeran.
The data met both primary and secondary endpoints, beating Keytruda monotherapy alone. Analysts have upgraded their ratings in response, with Morgan Stanley setting a $179 target price, while UBS downgraded to Neutral at $150, citing the move as 'broadly aligned with events.'
Merck & Co. is trading at fair value, with a Fair Value of $148.02, representing a -1.0% margin of safety. The stock's valuation metrics are inflationary, with a P/E LTM of 116.3x and a P/E Forward of 55.7x.
The technical picture is mixed, with the daily chart showing a Strong Buy signal but the weekly chart indicating exhaustion territory. A decisive hold above $149 keeps the bull thesis alive; a break below $147 would argue for patience into the October catalyst.